STOCK TITAN

Thermogenesis Holdings Inc - THMO STOCK NEWS

Welcome to our dedicated page for Thermogenesis Holdings news (Ticker: THMO), a resource for investors and traders seeking the latest updates and insights on Thermogenesis Holdings stock.

ThermoGenesis Holdings, Inc. (NASDAQ: THMO) drives innovation in automated cell therapy technologies, specializing in CAR-T manufacturing solutions and clinical biobanking systems. This page aggregates all official announcements, financial disclosures, and strategic developments for investors and industry professionals.

Access real-time updates on the CAR-TXpress platform advancements, facility expansions like the Sacramento CDMO complex with ISO 7 cleanrooms, and partnership announcements. Track quarterly financial results, leadership changes, and regulatory milestones impacting the cell therapy sector.

Key content includes earnings reports, product launch details, manufacturing capacity updates, and collaborations with biotech partners. The curated news feed enables efficient monitoring of THMO's transition from medical device specialist to full-service cell therapy CDMO.

Bookmark this page for streamlined access to verified information about ThermoGenesis' automated bioprocessing systems and cryopreservation technologies. Check regularly for developments affecting the $4.3B CAR-T market and broader cell therapy landscape.

Rhea-AI Summary
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) reported Q3 2023 financial results, highlighting a 3.7% increase in net revenues and a $3,615,000 net loss. The company also unveiled a new 35,500+ square foot CDMO facility in Sacramento, aiming to accelerate product development in the cell and gene therapy field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.18%
Tags
-
Rhea-AI Summary
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) announces Q3 financial results release and corporate update conference call on November 13, 2023. The company is a market leader in automated cell processing tools and services in the cell and gene therapy field. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada) or access a live webcast at https://thermogenesis.com/investors/news-and-events/events-webcasts/.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
-
Rhea-AI Summary
ThermoGenesis Holdings, Inc. announced the grand opening of its new facility, housing ISO 7 cGMP cleanroom suites and research labs. The facility will provide the cleanroom environment and services needed for R&D and manufacturing of cell and gene therapies. ThermoGenesis plans to transform into a cell and gene therapy services company and a contract development and manufacturing organization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
Rhea-AI Summary
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) will present a company overview during the H.C. Wainwright 25th Annual Global Investment Conference on September 13. CEO Chris Xu will also host one-on-one meetings during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
conferences
-
Rhea-AI Summary
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) reported financial and operating results for the second quarter ended June 30, 2023, with net revenues of $2.3 million, a decrease from the previous year. The company also highlighted the construction of innovative ReadyStart suites in Sacramento and the addition of new independent directors to the Board. ThermoGenesis will host a conference call to discuss these results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.59%
Tags
-
Rhea-AI Summary
ThermoGenesis Holdings, Inc. will release its financial results for Q2 2023 and provide a corporate strategic update on August 10, 2023. A conference call and webcast will follow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
Rhea-AI Summary
ThermoGenesis Holdings, Inc. appoints Biao Xi and James Xu to its Board of Directors. Xi is a highly regarded life science executive with extensive experience in biopharmaceutical research and drug development, while Xu brings strong legal and business acumen. Their expertise will strengthen ThermoGenesis' transition into a high-performance contract development and manufacturing organization in the cell and gene therapy field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

ThermoGenesis Holdings, Inc. (Nasdaq: THMO) reported a 13% increase in net revenues for 2022, reaching $10.5 million, driven by higher AXP disposable sales. However, gross profit fell to $2.7 million (26% of revenue), down from 38% due to increased manufacturing costs. The company reduced operating expenses by 15% to $7.2 million and R&D expenses by 25% to $1.7 million. Despite the improvements, a comprehensive net loss of $11.2 million was reported, with cash reserves down to $4.2 million. ThermoGenesis is transitioning to a CDMO model, launching 12 ReadyStart cGMP Suites projected to generate $10-$16 million annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
Thermogenesis Holdings Inc

Nasdaq:THMO

THMO Rankings

THMO Stock Data

5.37M
11.41M
28.02%
0.27%
Medical Devices
Laboratory Apparatus & Furniture
Link
United States
RANCHO CORDOVA